1. Home
  2. MIRM vs BANF Comparison

MIRM vs BANF Comparison

Compare MIRM & BANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • BANF
  • Stock Information
  • Founded
  • MIRM 2018
  • BANF 1984
  • Country
  • MIRM United States
  • BANF United States
  • Employees
  • MIRM N/A
  • BANF N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • BANF Major Banks
  • Sector
  • MIRM Health Care
  • BANF Finance
  • Exchange
  • MIRM Nasdaq
  • BANF Nasdaq
  • Market Cap
  • MIRM 3.8B
  • BANF 4.2B
  • IPO Year
  • MIRM 2019
  • BANF N/A
  • Fundamental
  • Price
  • MIRM $72.65
  • BANF $108.86
  • Analyst Decision
  • MIRM Strong Buy
  • BANF Hold
  • Analyst Count
  • MIRM 11
  • BANF 2
  • Target Price
  • MIRM $79.00
  • BANF $128.00
  • AVG Volume (30 Days)
  • MIRM 560.3K
  • BANF 109.4K
  • Earning Date
  • MIRM 11-04-2025
  • BANF 10-17-2025
  • Dividend Yield
  • MIRM N/A
  • BANF 1.80%
  • EPS Growth
  • MIRM N/A
  • BANF 13.17
  • EPS
  • MIRM N/A
  • BANF 7.04
  • Revenue
  • MIRM $429,161,000.00
  • BANF $666,553,000.00
  • Revenue This Year
  • MIRM $53.14
  • BANF $11.96
  • Revenue Next Year
  • MIRM $19.83
  • BANF $3.80
  • P/E Ratio
  • MIRM N/A
  • BANF $15.46
  • Revenue Growth
  • MIRM 62.33
  • BANF 9.57
  • 52 Week Low
  • MIRM $36.88
  • BANF $97.02
  • 52 Week High
  • MIRM $78.55
  • BANF $138.77
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 52.77
  • BANF 27.53
  • Support Level
  • MIRM $68.34
  • BANF $108.94
  • Resistance Level
  • MIRM $71.96
  • BANF $112.84
  • Average True Range (ATR)
  • MIRM 2.53
  • BANF 3.29
  • MACD
  • MIRM -0.13
  • BANF -0.44
  • Stochastic Oscillator
  • MIRM 56.54
  • BANF 5.19

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About BANF BancFirst Corporation

BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.

Share on Social Networks: